WO2026007830 - CD7-TARGETING NANOBODY AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/007830
Publication Date
08.01.2026
International Application No.
PCT/CN2025/104398
International Filing Date
27.06.2025
Title **
[English]
CD7-TARGETING NANOBODY AND USE THEREOF
[French]
NANOCORPS CIBLANT CD7 ET SON UTILISATION
[Chinese]
一种靶向CD7的纳米抗体及其应用
Applicants **
SHENZHEN GENOCURY BIOTECH CO., LTD
Inventors
HUANG, Ke
LI, Yuhang
Priority Data
202410887728.4
03.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1973 | |
| EPO | Filing, Examination, Granting | 12597 | |
| Japan | Filing, Examination, Granting | 2154 | |
| South Korea | Filing, Examination, Granting | 2132 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,596
Contact Us
Abstract[English]
The present invention relates to the field of nanobodies, and specifically relates to a CD7-targeting nanobody and a use thereof. Disclosed is a CD7-targeting nanobody. The nanobody has a small molecular weight and low immunogenicity, and is more suitable for clinical applications such as cell therapy and gene therapy.[French]
La présente invention relève du domaine des nanocorps, et concerne en particulier un nanocorps ciblant CD7 et son utilisation. L'invention concerne un nanocorps ciblant CD7. Le nanocorps a un faible poids moléculaire et une faible immunogénicité, et est plus approprié pour des applications cliniques telles que la thérapie cellulaire et la thérapie génique.[Chinese]
涉及纳米抗体领域，具体涉及一种靶向CD7的纳米抗体及其应用。公开了一种靶向CD7的纳米抗体，所述纳米抗体的分子量小且免疫原性低，更适合被应用于细胞疗法和基因疗法等临床运用中。